Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04810715
Other study ID # NEAS2021
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2021
Est. completion date September 1, 2022

Study information

Verified date September 2022
Source Afyonkarahisar Health Sciences University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This investigation aims to investigate the frequency of pes planus and posterior tibial tendon dysfunction in patients with ankylosing spondylitis.


Description:

Posterior tibial tendon dysfunction is the most common cause of acquired pes planus deformity in healthy adults. The posterior tibial tendon stabilizes the hindfoot against valgus and eversion forces and acts as a support along the medial longitudinal arch. If the posterior tibial tendon loses its functionality, the other ligaments of the foot and the joint capsule gradually weaken as the height of the medial longitudinal arch decreases or disappears, and it develops with pes planus. The presence of pes planus and spondyloarthropathy are also risk factors for the development of posterior tibial tendon dysfunction. 100 participants aged between 20-70 years with ankylosing spondylitis were planned to be included in this investigation. Posterior tibial tendon dysfunction frequency of patients with ankylosing spondylitis will be evaluated by both clinical examination and musculoskeletal ultrasonography device. The posterior tibial tendon will be evaluated by ultrasonography in terms of tendon diameter and fluid presence in 2 different locations in the retromalleolar area. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Quality of Life (ASQoL) Scale, Functional reach test, Timed up and go test, Berg Balance Scale, Dynamic and static balance with the Sportkat device will be used as evaluation parameters. It was planned that the evaluations were made once.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date September 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: - Participitans who apply to the rheumatology outpatient clinic between the ages of 20-70 and who have been diagnosed with ankylosing spondylitis according to the Modified Newyork criteria will be included in this study. 1. Ankylosing Spondilitis Exclusion Criteria: 1. Malignity 2. Previous ankle surgery history 3. Muscle disease 4. Neuropsychiatric illnesses 5. Imbalance 6. Visual problems 7. Deafness

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Patients with Ankylosing Spondylitis
Observational study, not applicable

Locations

Country Name City State
Turkey Afyonkarahisar Afyonkarahisar

Sponsors (1)

Lead Sponsor Collaborator
Afyonkarahisar Health Sciences University

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Arnoldner MA, Gruber M, Syré S, Kristen KH, Trnka HJ, Kainberger F, Bodner G. Imaging of posterior tibial tendon dysfunction--Comparison of high-resolution ultrasound and 3T MRI. Eur J Radiol. 2015 Sep;84(9):1777-81. doi: 10.1016/j.ejrad.2015.05.021. Epub 2015 May 21. — View Citation

Guelfi M, Pantalone A, Mirapeix RM, Vanni D, Usuelli FG, Guelfi M, Salini V. Anatomy, pathophysiology and classification of posterior tibial tendon dysfunction. Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):13-19. Review. — View Citation

Hasler P, Hintermann B, Meier M. Posterior tibial tendon dysfunction and MR imaging in rheumatoid arthritis. Rheumatol Int. 2002 May;22(1):38-40. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) BASDAI includes six questions evaluating five important findings of the disease (Fatigue, hip and spine pain, swelling and pain in peripheral joints, enthesitis, duration and severity of morning stiffness). The pain levels of the patients will be evaluated with a Visual Analog scale (0: I have no pain, 10: I have very severe pain).
Higher scores mean active disease.
Will be done only once on the first day after inclusion
Primary Bath Ankylosing Spondylitis Functional Index (BASFI) BASFI; consists of eight questions that evaluate the function of patients with AS and two questions that evaluate their daily life. Higher scores indicate greater limitations. Will be done only once on the first day after inclusion
Primary Ankylosing Spondylitis Quality of Life Scale (ASQOL) Ankylosing Spondylitis Quality of Life (ASQoL) scale is a disease-specific assessment parameter designed to measure health-related quality of life. It includes yes or no questions with a total score ranging from 0 to 18. The lower scores represent better quality of life. Will be done only once on the first day after inclusion
Secondary Functional reach test Functional reach test: It is the maximum distance that the participants can reach forward in the horizontal plane while maintaining her/his stability on the support surface in the standing position. Will be done only once on the first day after inclusion
Secondary Timed up and go test (TUG) The TUG test is a simple evaluative test used to measure functional mobility. It uses the time that participants take to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while turning 180 degrees. During the test, the participant is expected to wear their regular footwear and use any mobility aids that they would normally require.11-20 seconds are within normal limits for frail elderly and disabled patients, and greater than 20 seconds means the worse scores. Will be done only once on the first day after inclusion
Secondary Berg Balance Scale The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function and takes approximately 20 minutes to complete. The total score is 56. A score of < 45 indicates participants may be at greater risk of falling. Will be done only once on the first day after inclusion
Secondary Foot and Ankle Outcome Score (FAOS) The FAOS is a 42-item questionnaire assessing patient-relevant outcomes in five separate subscales (Pain, other Symptoms, Activities of daily living, Sport and recreation function, foot and ankle-related Quality of life). Scores range from 0 to 100 with a score of 0 indicating the worst possible foot/ankle symptoms and 100 indicating no foot/ankle symptoms. Lower scores mean the worse scores. Will be done only once on the first day after inclusion
Secondary Ultrasonographic evaluation of the posterior tibial tendon Posterior tibial tendon evaluation will be evaluated in 2 different locations in the retromalleolar area.Tendon diameter, continuity and fluid presence will be evaluated ultrasonographically. Power Doppler signal levels will be graded on a 4-point semi-quantitative scale (none-grade 0 / minor-grade 1 / middle-grade 2 / severe-grade 3). Will be done only once on the first day after inclusion
Secondary Static and Dynamic Balance measurment with SportKAT Device. The SportKAT device used for determining postural oscillation consists of a balance platform and sensors that detect oscillations.There is a screen in front of the participant standing on the platform to provide feedback. During the static balance test, it is asked to keep the 'X' mark seen on the screen constant in the center. During the dynamic balance test, it is asked to to follow the moving cursor. The score range varies between 0 and 6000. The lower the score, the better the balance. Will be done only once on the first day after inclusion
See also
  Status Clinical Trial Phase
Completed NCT01208207 - A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) Phase 3
Completed NCT02509026 - Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA Phase 4
Completed NCT02704845 - Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain N/A
Terminated NCT01209702 - A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs Phase 3
Terminated NCT01209689 - A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy Phase 3
Terminated NCT00766402 - An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs) Phase 4
Completed NCT00000433 - Blocking Tumor Necrosis Factor in Ankylosing Spondylitis Phase 2
Completed NCT00779935 - Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) Phase 4
Completed NCT00779012 - A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) Phase 4
Completed NCT01863732 - Extension in AS: Sustainability of Benefits, Safety and Tolerability Phase 3
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Completed NCT01567878 - Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects N/A
Completed NCT01188655 - Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis N/A
Completed NCT00760669 - An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Phase 4
Completed NCT02159053 - 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT00202865 - Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) Phase 3
Completed NCT02374502 - Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial N/A
Terminated NCT00273858 - Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis N/A
Withdrawn NCT00298012 - Methotrexate in the Treatment of Axial Spondyloarthritis Phase 4
Completed NCT03880968 - Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis